262 related articles for article (PubMed ID: 35134917)
1. Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study.
Thomas PWA; den Broeder N; Derikx M; Kievit W; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F
Inflamm Bowel Dis; 2022 Dec; 28(12):1813-1820. PubMed ID: 35134917
[TBL] [Abstract][Full Text] [Related]
2. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
[TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life in Patients with Inflammatory Bowel Disease in Clinical Remission: What Should We Look For?
Stroie T; Preda C; Meianu C; Croitoru A; Gheorghe L; Gheorghe C; Diculescu M
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454325
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
5. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
6. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports.
Momen Majumder MS; Haq SA; Rasker JJ
J Med Case Rep; 2023 Mar; 17(1):71. PubMed ID: 36855206
[TBL] [Abstract][Full Text] [Related]
8. FACTORS ASSOCIATED WITH CIRCULATING ZONULIN IN INFLAMMATORY BOWEL DISEASE.
Lacombe LAC; Matiollo C; Rosa JSD; Felisberto M; Dalmarco EM; Schiavon LL
Arq Gastroenterol; 2022; 59(2):238-243. PubMed ID: 35830035
[TBL] [Abstract][Full Text] [Related]
9. Agreement between patients and physicians on scores of inflammatory bowel disease activity and burden assessed on a telemonitoring platform.
Mangia M; Giuffrida E; Figini V; Colombo A; Carli E; Lavagna A; Mendolaro M; Morello E; Cosimato M; Rocca R; Pagana G; Daperno M
Scand J Gastroenterol; 2023 Mar; 58(3):240-247. PubMed ID: 36148538
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
Bellone F; Morace C; Impalà G; Viola A; Lo Gullo A; Cinquegrani M; Fries W; Sardella A; Scolaro M; Basile G; Squadrito G; Mandraffino G
J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373936
[TBL] [Abstract][Full Text] [Related]
14. Examination of the relationship between disease activity and patient-reported outcome measures in an inflammatory bowel disease cohort.
Jackson BD; Con D; Gorelik A; Liew D; Knowles S; De Cruz P
Intern Med J; 2018 Oct; 48(10):1234-1241. PubMed ID: 29663629
[TBL] [Abstract][Full Text] [Related]
15. Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use.
Subramanian S; Asher R; Weston W; Rimmer M; McConville A; Malin A; Jackson R; Collins P; Probert C; Dibb M; Rhodes JM
Inflamm Bowel Dis; 2016 Aug; 22(8):1902-7. PubMed ID: 27243590
[TBL] [Abstract][Full Text] [Related]
16. Impaired Quality of Working Life in Inflammatory Bowel Disease Patients.
van Gennep S; de Boer NKH; Gielen ME; Rietdijk ST; Gecse KB; Ponsioen CY; Duijvestein M; D'Haens GR; Löwenberg M; de Boer AGEM
Dig Dis Sci; 2021 Sep; 66(9):2916-2924. PubMed ID: 33063191
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
18. Utility of routinely collected electronic health records data to support effectiveness evaluations in inflammatory bowel disease: a pilot study of tofacitinib.
Rudrapatna VA; Glicksberg BS; Butte AJ
BMJ Health Care Inform; 2021 May; 28(1):. PubMed ID: 34011632
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
Borren NZ; Tan W; Colizzo FP; Luther J; Garber JJ; Khalili H; van Der Woude CJ; Ananthakrishnan AN
J Crohns Colitis; 2020 Mar; 14(3):309-315. PubMed ID: 31504365
[TBL] [Abstract][Full Text] [Related]
20. Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.
Wyatt NJ; Watson H; Anderson CA; Kennedy NA; Raine T; Ahmad T; Allerton D; Bardgett M; Clark E; Clewes D; Cotobal Martin C; Doona M; Doyle JA; Frith K; Hancock HC; Hart AL; Hildreth V; Irving PM; Iqbal S; Kennedy C; King A; Lawrence S; Lees CW; Lees R; Letchford L; Liddle T; Lindsay JO; Maier RH; Mansfield JC; Marchesi JR; McGregor N; McIntyre RE; Ostermayer J; Osunnuyi T; Powell N; Prescott NJ; Satsangi J; Sharma S; Shrestha T; Speight A; Strickland M; Wason JM; Whelan K; Wood R; Young GR; Zhang X; Parkes M; Stewart CJ; Jostins-Dean L; Lamb CA
BMJ Open; 2024 Apr; 14(4):e073639. PubMed ID: 38631839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
